Physician profile
Kyla Dewar
NPI 1912260746
$585.97
in general payments reported to CMS, 2019-2025
15 companies · $17.15 in 2025
The $17.15 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $149 · 2023: $17.40 · 2025: $17.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $90.47 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $80.86 | 2019-2020 | |
| Lilly USA, LLC | $75.41 | 2019-2020 | |
| Amgen INC. | $75.17 | 2019-2025 | Prolia, Evenity |
| Pfizer INC. | $37.62 | 2019-2020 | |
| Astellas Pharma US INC | $37.52 | 2019-2020 | |
| Novo Nordisk INC | $35.22 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $28.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.06 | 2019 | |
| Allergan, INC. | $23.57 | 2020 | |
| Ge Healthcare | $19.50 | 2019 | |
| Abbvie INC. | $17.40 | 2023 | Qulipta |
| Sunovion Pharmaceuticals INC. | $16.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.73 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyla Dewar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.